Article PDF first page preview

First page of 14 biomarkers and subsequent disability in patients with stroke recurrence: results from the SPARCL trial

Objectives: In patients enrolled in the SPARCL trial levels of osteopontin, neopterin, N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP), myeloperoxidase, monocyte chemoattractant protein-1 (MCP-1), resistin, matrix metalloproteinase-9 (MMP-9), adiponectin, high-sensitive C-reactive Protein (hsCRP), lipoprotein-associated phospholipase-A2 (Lp-PLA2), soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble CD40-ligand (sCD40L) and HDL-Cholesterol (HDL-c) were measured 1-6 months after the qualifying stroke or TIA . We determined whether any of these biomarkers were associated with disability in case of recurrence. Material and Methods: Among 463 recurrent strokes, the associations of these biomarkers with the National Institutes of Health-Stroke Scale (NIHSS), Barthel Index, and modified Rankin Score (mRS) measured after 90-days were assessed. Using adjusted logistic regression analysis, biomarker levels were compared between unfavorable versus favorable outcome (NIHSS>2 versus 0-1; Barthel Index <95 versus 95-100; and mRS 2-6 versus 0-1). Results: Higher baseline levels of osteopontin (OR:1.166; CI95%:1.01-1.347, p=0.0367) and neopterin (OR:1.531; CI95%:1.07-2.188, p=0.0195) predicted poorer outcomes after recurrent stroke. For participants with ischemic stroke, higher levels of neopterin (OR:1.488, CI95%:1.022-2.167, p=0.0384) and NT-proBNP, (OR1.399, CI95%:1.035-1.891, p=0.0289) were predictor of unfavorable mRS. Analyses including stroke and TIA showed that lower HDL-c levels were associated with an unfavorable mRS (OR:0.564, CI 95% 0.328-0.971, p=0.0387). Conclusions: Higher levels of osteopontin, neopterin and NT-ProBNP and lower levels of HDL-c after stroke were independently associated with greater disability in case of recurrent stroke.

Journal Section:
Clinical Neurology
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.